SCHEDULE 13G/A: BlackRock Discloses 14.7% Stake in Supernus Pharmaceuticals

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 14.7% beneficial ownership stake in Supernus Pharmaceuticals, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 8,197,023 shares of Supernus Pharmaceuticals, Inc. common stock.
• This ownership represents 14.7% of the total outstanding common stock of Supernus Pharmaceuticals, Inc.
• BlackRock holds sole voting power over 8,092,706 shares and sole dispositive power over all 8,197,023 shares.
• The filing is an Amendment No. 5 to a Schedule 13G, indicating an update to previously reported ownership.
• The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• BlackRock Fund Advisors and iShares Core S&P Small-Cap ETF, both affiliated with BlackRock, each beneficially own more than 5% of the outstanding common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing an institutional ownership stake. It does not contain information that would inherently convey positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• The significant stake held by a major institutional investor like BlackRock could be interpreted as a vote of confidence in Supernus Pharmaceuticals' long-term prospects.

Future Outlook

This document does not provide any forward-looking statements or guidance regarding Supernus Pharmaceuticals, Inc.'s future performance or strategic outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's voting stock, indicating a passive investment intent. BlackRock, as one of the world's largest asset managers, frequently files such documents as part of its routine investment activities across various sectors, including pharmaceuticals. This filing reflects BlackRock's continued or adjusted passive investment in Supernus Pharmaceuticals, a company operating in the pharmaceutical industry.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of a passive ownership stake by a large institutional investor. It does not contain performance metrics or operational details of Supernus Pharmaceuticals that would allow for a direct comparison to industry standards or specific comparable companies/projects. The 14.7% stake is a significant institutional holding, common for large asset managers like BlackRock across their diverse portfolios.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holding by BlackRock may provide a degree of confidence or stability, indicating a large, passive investor believes in the company's long-term prospects.
• Management: Awareness of a large institutional holder may influence management's strategic decisions, though BlackRock's stated intent is passive.

Key Dates

Recommendation

Keywords

Supernus Pharmaceuticals, BlackRock, Schedule 13G, Institutional Ownership, Common Stock, Beneficial Ownership, Pharmaceuticals, Investment Management, SEC Filing